Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.05 USD | +0.80% | -1.60% | -13.30% |
05-02 | UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating | MT |
05-01 | Alkermes's Q1 Earnings, Revenue Grow But Miss Street View | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.30% | 4.04B | |
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |
- Stock Market
- Equities
- ALKS Stock
- News Alkermes plc
- Alkermes : Presents Nemvaleukin Alfa Data at American Society of Clinical Oncology Annual Meeting